Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:80525
Name differentiated high-grade thyroid carcinoma
Definition A thyroid gland adenocarcinoma characterized by extensive evidence of follicular cell differentiation.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid cancer thyroid gland carcinoma thyroid gland adenocarcinoma differentiated high-grade thyroid carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
NRAS mutant Pazopanib + Trametinib differentiated high-grade thyroid carcinoma predicted - sensitive detail...
RET fusion Selpercatinib differentiated high-grade thyroid carcinoma sensitive detail...
RET fusion Pralsetinib differentiated high-grade thyroid carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03475953 Phase Ib/II Avelumab + Regorafenib A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) Recruiting FRA 0
NCT03732495 Phase II Denosumab + Lenvatinib Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (LENVOS) Unknown status FRA 0
NCT03753919 Phase II Durvalumab + Tremelimumab Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY) Terminated ESP 0
NCT04514484 Phase I Cabozantinib + Nivolumab Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Active, not recruiting USA 0
NCT04544111 Phase II Dabrafenib + Spartalizumab Spartalizumab + Trametinib PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Active, not recruiting USA 0
NCT05783323 Phase II Larotrectinib Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer Recruiting USA 0
NCT06007924 Phase II Defactinib + RO5126766 A Study of Avutometinib and Defactinib in People With Thyroid Cancer Recruiting USA 0
NCT06235216 Phase II Sacituzumab govitecan-hziy Sacituzumab govitEcan in THYroid Cancers (SETHY) Recruiting ESP 0